INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 50 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $24,000 | +9.1% | 30,000 | +3.4% | 0.00% | – |
| Q2 2020 | $22,000 | -12.0% | 29,000 | -6.5% | 0.00% | -100.0% |
| Q1 2020 | $25,000 | -16.7% | 31,000 | +3.3% | 0.00% | 0.0% |
| Q4 2019 | $30,000 | +11.1% | 30,000 | -3.2% | 0.00% | 0.0% |
| Q3 2019 | $27,000 | -3.6% | 31,000 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $28,000 | 0.0% | 31,000 | +10.7% | 0.00% | 0.0% |
| Q1 2019 | $28,000 | -3.4% | 28,000 | -12.5% | 0.00% | 0.0% |
| Q4 2018 | $29,000 | -14.7% | 32,000 | -5.9% | 0.00% | 0.0% |
| Q3 2018 | $34,000 | +17.2% | 34,000 | +3.0% | 0.00% | 0.0% |
| Q2 2018 | $29,000 | +11.5% | 33,000 | +3.1% | 0.00% | 0.0% |
| Q1 2018 | $26,000 | 0.0% | 32,000 | -5.9% | 0.00% | 0.0% |
| Q4 2017 | $26,000 | 0.0% | 34,000 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $26,000 | -31.6% | 34,000 | -12.8% | 0.00% | 0.0% |
| Q2 2017 | $38,000 | +5.6% | 39,000 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $36,000 | – | 39,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Man Investments (CH) AG | 3,300,000 | $2,640,000 | 2.48% |
| SYMPHONY ASSET MANAGEMENT LLC | 14,000,000 | $11,200,000 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 36,000,000 | $28,879,000 | 1.14% |
| Opera Trading Capital | 5,500,000 | $4,344,000 | 0.89% |
| MACKAY SHIELDS LLC | 17,789,000 | $14,221,000 | 0.52% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 24,415,000 | $19,539,000 | 0.37% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 6,000,000 | $4,918,000 | 0.37% |
| OAKTREE CAPITAL MANAGEMENT LP | 28,415,000 | $22,732,000 | 0.36% |
| GLG Partners LP | 8,700,000 | $6,960,000 | 0.33% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 42,285,000 | $33,828,000 | 0.28% |